Bases fisiopatológicas y consecuencias de la fiebre

1. O’Grady NP, Barie PS, Bartlett JG, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med. 2008;36:1330–49.

2. Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intens Care Med. 1999;25(7):668–73.

3. Zimmerman JL, Hanania NA. Hyperthermia. In: Hall JB, Schmidt GA, Wood LDH, editors. Principles of critical care. 3rd ed. New York, NY: McGraw-Hill Inc; 2005. p. 1678.

4. Macallan DC. Hyperthermia and pyrexia. In: Webb AR, Shapiro MJ, Singer M, Suter PM, editors. Oxford textbook of critical care. 1st ed. Oxford, UK: OUP; 1999. p. 797.

5. Kaul DR, Flanders SA, Beck JM, Saint S. Incidence, etiology, risk factors, and outcome of hospital-acquired fever. J Gen Intern Med. 2006;21(11):1184–7.

6. Bor DH, Makadon HJ, Friedland G, Dasse P, Komaroff AL, Aronson MD. Fever in hospitalized medical patients: characteristics and significance. J Gen

Intern Med. 1988;3:119–25.

7. Sanchez-Alavez M, Tabarean IV, Behrens MM, Bartfai T. Ceramide mediates the rapid phase of febrile response to IL-1β. Proc Natl Acad Sci U S A. 2006;103(8):2904–8.

8. Gross L. Anatomy of a Fever. PLoS Biol. 2006;4(9):e305.

9. Li Z, Perlik V, Feleder C, Tang Y, Blatteis CM. Kupffer cell-generated PGE2 triggers the febrile response of guinea pigs to intravenously injected LPS. Am J Physiol – Reg I. 2006;290(5):R1262–70.

10. Launey Y, Nesseler N, Mallédant Y, Seguin P. Clinical review: Fever in septic ICU patients—friend or foe? Crit Care. 2011;15:222.

11. Roth J, de Souza GEP. Fever induction pathways: evidence from responses to systemic or local cytokine formation. Braz J Med Biol Res. 2001;34(3):301–14.

12. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004;10(4):201–22.

13. Young PJ, Saxena M, Beasley R, et al. Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med. 2012;38:437–44.

14. Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012;16(1):R33.

15. Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. South Med J. 1997;90:296–8.

16. Leroy O, Gangneux J, Montravers P, Mira J, Gouin F, Sollet J, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8.

17. Small PM, Täuber MG, Hackbarth CJ, Sande MA. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun. 1986;52(2):484–7.

18. Mackowiak PA, Marling-Cason M, Cohen RL. Effects of temperature on antimicrobial susceptibility of bacteria. J Infect Dis. 1982;145(4):550–3.

19. Rice P, Martin E, He J, Frank M, DeTolla L, Hester L, et al. Febrile-range hyperthermia augments neutrophil accumulation and enhances lung injury in experimental Gram negative bacterial pneumonia. J Immunol. 2005;174:3676–85.

20. Beverly A, Walter E, Carraretto M. Management of hyperthermia and hypothermia in sepsis: a recent survey of current practice across UK intensive care units. JICS. 2016;17:88–9.

21. Toussaint E, Bahel-Ball E, Vekemans M, Georgala A, Al-Hakak L, Paesmans M, et al. Causes of fever in cancer patients. Support Care Cancer. 2006;14:763.

22. Dinarello CA. Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. Innate Immun. 2004;10:201–22.

23. Walter EJ, Carraretto M. Drug-induced hyperthermia in critical care. JICS. 2015;16(4):306–11.

24. Dao CK, Nowinski SM, Mills EM. The heat is on: molecular mechanisms of drug-induced hyperthermia. Temperature. 2014;1(3):183–91.

25. Crompton MR. Hypothalamic lesions following closed head injury. Brain. 1971;94:165–72.

26. 26. Chomova M, Zitnanova I. Look into brain energy crisis and membrane pathophysiology in ischemia and reperfusion. Stress. 2016;1–8. [Epub ahead of print].

27. Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab. 2011;31:658–70.

28. Mrozek S, Vardon F, Geeraerts T. Brain temperature: physiology and pathophysiology after brain injury. Anesthesiol Res Pract. 2012;2012:989487.

29. Normoyle KP, Kim M, Farahvar A, Llano D, Jackson K, Wang H. The emerging neuroprotective role of mitochondrial uncoupling protein-2 in traumatic brain injury. Transl Neurosci. 2015;6:179–86.

30. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syndrome. epidemiology, pathophysiology, treatment, and prognostication a consensus statement. Circulation. 2008;118:2452–83.

31. Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid. 2012;22:661–79.

32. Alvarez-Crespo M, Csikasz RI, Martínez-Sánchez N, Diéguez C, Cannon B, Nedergaard J, et al. Essential role of UCP1 modulating the central effects of thyroid hormones on energy balance. Mol Metab. 2016;5:271–82.

33. Ljunggren JG, Kallner G, Tryselius M. The effect of body temperature on thyroid hormone levels in patients with non-thyroidal illness. Acta Med Scand. 1977;202:459–62.

34. Addison T. On the constitutional and local effects of disease of the supra-renal capsules. Samuel Highley: London, UK; 1855.

35. Gordon DL, Atamian SD, Brooks MH, Gattuso P, Castelli MJ, Valaitis J, et al. Fever in pheochromocytoma. Arch Intern Med. 1992;152:1269–72.

36. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hemat. 2002;43:33–56.

37. Roti JL. Cellular responses to hyperthermia (40–46 °C): cell killing and molecular events. Int J Hyperther. 2008;24(1):3–15.

38. Dieing A, Ahlers O, Hildebrandt B, Kerner T, Tamm I, Possinger K, Wust P. The effect of induced hyperthermia on the immune system. Prog Brain Res. 2007;162:137–52.

39. Bouchama A, Al-Sedairy S, Siddiqui S, Shail E, Rezeig M. Elevated pyrogenic cytokines in heatstroke. Chest. 1993;104(5):1498–502.

40. Hashim IA, Al-Zeer A, Al-Shohaib S, Al-Ahwal M, Shenkin A. Cytokine changes in patients with heatstroke during pilgrimage to Makkah. Mediat Inflamm. 1997;6:135–9.

41. Phillips NA, Welc SS, Wallet SM, King MA, Clanton TL. Protection of intestinal injury during heat stroke in mice by interleukin-6 pretreatment. J Physiol. 2015;593(3):739–52.

42. Chiu WT, Kao TY, Lin MT. Interleukin-1 receptor antagonist increases survival in rat heatstroke by reducing hypothalamic serotonin release. Neurosci Lett. 1995;202(1–2):33–6.

43. Heled Y, Fleischmann C, Epstein Y. Cytokines and their role in hyperthermia and heat stroke. J Basic Clin Physiol Pharmacol. 2013;24(2):85–96.

44. Rosebush PI, Anglin RE, Richards C, et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008;28:459–61.

45. Anglin RE, Rosebush PI, Mazurek MF. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ. 2010;182(18):E834–8.

46. Kamińska T, Szuster-Ciesielska A, Wysocka A, Marmurowska-Michałowska H, Dubas-Slemp H, Kandefer-Szerszeń M. Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics. Med Sci Monit. 2003;9(7):CS71–5.